MOTS-c, Metabolism & Insulin Sensitivity: From Preclinical Research to Phase 2a

Mouse metabolic research, 2015

Lee and colleagues titled the discovery paper around metabolic homeostasis, obesity, and insulin resistance. The title is broad. The intervention work that supports those words was, in large part, preclinical.¹

This page follows that hypothesis to the current trial. It does not claim weight loss, diabetes treatment, or improved insulin sensitivity in people. The map is in the MOTS-c hub.

The insulin-sensitivity hypothesis

The hypothesis says, briefly, that MOTS-c might influence insulin-related metabolic readouts. It was born in models and in mechanisms — skeletal muscle, AMPK, folate and purine pathways — not in a mature clinical program.¹

A hypothesis is a question. NCT07505745 is the current attempt to pose that question in a randomized design in adults with prediabetes and overweight or obesity. The design does not anticipate the answer.⁵

The registry title speaks of improving insulin sensitivity. That is the trial’s research objective, not a finding. Until results are posted, the verb “improve” belongs to the protocol, not to the evidence.

Observational evidence versus treatment evidence

People have endogenous MOTS-c. It has been measured in exercise and in disease cohorts. Those measurements can associate with metabolic, aging, or kidney variables. Association is not therapeutic efficacy.^3,4

A reader can see “human metabolism study” and hear “patients were given the peptide.” That reading is false when the study only measured what the body already made.⁴

The same caution applies to aging or exercise associations. A higher or lower circulating level does not show that administering the peptide corrects a metabolic problem.

NCT07505745

The registry name is MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. The short name is MOTS-MET. The official design is Phase 2a, randomized, double-blind, and placebo-controlled.⁵

Study start is 2 February 2026. The last update posted that we use is 1 April 2026. Estimated enrollment is 120. Estimated primary completion is 14 February 2027; estimated study completion is 17 May 2028. The status reviewed on 1 September 2026 is Recruiting.⁵

The trial exists to study controlled human administration. It is not reproduced here as a how-to. The registry may contain intervention information; this page does not turn that information into a dose, a frequency, or a protocol.

Describing the design — randomized, double-blind, placebo, estimated enrollment of 120 — is enough to place the study. An administration recipe extracted from the registry is not needed and is not offered.

No results posted

FDA, in the July 2026 briefing, could note the lack of human data from products containing MOTS-c-related bulk substances at the same time a trial is registered. The two facts do not contradict each other: a trial record is not trial results.^6,5

What is not claimed

• It is not claimed that MOTS-c produces weight loss in people.
• It is not claimed that it treats diabetes.
• It is not claimed that it improves insulin sensitivity in people.⁵
• It is not claimed that the 2015 preclinical work already answered the clinical question.¹

Reynolds and the exercise work inform muscle and physiology. They do not close the human-administration metabolic question.²

The human inventory is in MOTS-c in humans. Regulatory status is in FDA and WADA.